Cargando…

Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations

BACKGROUND: Fas ligand (FasL) is one ligand that activates extrinsic apoptosis pathway. High expression in lymphocytes of FasL have been found in patients with acute rejection of liver transplantation (LT). No high blood concentrations of soluble FasL (sFasL) have been found in patients with acute L...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorente, Leonardo, Rodriguez, Sergio T, Sanz, Pablo, González-Rivero, Agustín F, Pérez-Cejas, Antonia, Padilla, Javier, Díaz, Dácil, González, Antonio, Martín, María M, Jiménez, Alejandro, Cerro, Purificación, Portero, Julián, Barrera, Manuel A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037289/
https://www.ncbi.nlm.nih.gov/pubmed/36970008
http://dx.doi.org/10.12998/wjcc.v11.i8.1753
_version_ 1784911845885214720
author Lorente, Leonardo
Rodriguez, Sergio T
Sanz, Pablo
González-Rivero, Agustín F
Pérez-Cejas, Antonia
Padilla, Javier
Díaz, Dácil
González, Antonio
Martín, María M
Jiménez, Alejandro
Cerro, Purificación
Portero, Julián
Barrera, Manuel A
author_facet Lorente, Leonardo
Rodriguez, Sergio T
Sanz, Pablo
González-Rivero, Agustín F
Pérez-Cejas, Antonia
Padilla, Javier
Díaz, Dácil
González, Antonio
Martín, María M
Jiménez, Alejandro
Cerro, Purificación
Portero, Julián
Barrera, Manuel A
author_sort Lorente, Leonardo
collection PubMed
description BACKGROUND: Fas ligand (FasL) is one ligand that activates extrinsic apoptosis pathway. High expression in lymphocytes of FasL have been found in patients with acute rejection of liver transplantation (LT). No high blood concentrations of soluble FasL (sFasL) have been found in patients with acute LT rejection; however, the samples size of those studies was small. AIM: To determine whether patients with hepatocellular carcinoma (HCC) that dead during the first year of LT have higher blood sFasL concentrations previously to LT that those who that remain alive in a study of higher sample size. METHODS: Patients underwent LT due to HCC were included in this retrospective study. Serum sFasL levels prior to LT were measured and one-year LT mortality was registered. RESULTS: Non-surviving patients (n = 14) showed higher serum sFasL levels [477 (269-496) vs 85 (44-382) pg/mL; P < 0.001] than surviving patients (n = 113). Serum sFasL levels (pg/mL) were associated with mortality (OR = 1.006; 95%CI = 1.003-1.010; P = 0.001) independently of age of LT donor in the logistic regression analysis. CONCLUSION: We report for the first time that HCC patients who die within the first year of HT have higher blood sFasL concentrations prior to HT than those who remain alive.
format Online
Article
Text
id pubmed-10037289
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-100372892023-03-25 Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations Lorente, Leonardo Rodriguez, Sergio T Sanz, Pablo González-Rivero, Agustín F Pérez-Cejas, Antonia Padilla, Javier Díaz, Dácil González, Antonio Martín, María M Jiménez, Alejandro Cerro, Purificación Portero, Julián Barrera, Manuel A World J Clin Cases Retrospective Study BACKGROUND: Fas ligand (FasL) is one ligand that activates extrinsic apoptosis pathway. High expression in lymphocytes of FasL have been found in patients with acute rejection of liver transplantation (LT). No high blood concentrations of soluble FasL (sFasL) have been found in patients with acute LT rejection; however, the samples size of those studies was small. AIM: To determine whether patients with hepatocellular carcinoma (HCC) that dead during the first year of LT have higher blood sFasL concentrations previously to LT that those who that remain alive in a study of higher sample size. METHODS: Patients underwent LT due to HCC were included in this retrospective study. Serum sFasL levels prior to LT were measured and one-year LT mortality was registered. RESULTS: Non-surviving patients (n = 14) showed higher serum sFasL levels [477 (269-496) vs 85 (44-382) pg/mL; P < 0.001] than surviving patients (n = 113). Serum sFasL levels (pg/mL) were associated with mortality (OR = 1.006; 95%CI = 1.003-1.010; P = 0.001) independently of age of LT donor in the logistic regression analysis. CONCLUSION: We report for the first time that HCC patients who die within the first year of HT have higher blood sFasL concentrations prior to HT than those who remain alive. Baishideng Publishing Group Inc 2023-03-16 2023-03-16 /pmc/articles/PMC10037289/ /pubmed/36970008 http://dx.doi.org/10.12998/wjcc.v11.i8.1753 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Study
Lorente, Leonardo
Rodriguez, Sergio T
Sanz, Pablo
González-Rivero, Agustín F
Pérez-Cejas, Antonia
Padilla, Javier
Díaz, Dácil
González, Antonio
Martín, María M
Jiménez, Alejandro
Cerro, Purificación
Portero, Julián
Barrera, Manuel A
Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations
title Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations
title_full Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations
title_fullStr Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations
title_full_unstemmed Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations
title_short Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations
title_sort patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sfasl concentrations
topic Retrospective Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037289/
https://www.ncbi.nlm.nih.gov/pubmed/36970008
http://dx.doi.org/10.12998/wjcc.v11.i8.1753
work_keys_str_mv AT lorenteleonardo patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations
AT rodriguezsergiot patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations
AT sanzpablo patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations
AT gonzalezriveroagustinf patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations
AT perezcejasantonia patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations
AT padillajavier patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations
AT diazdacil patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations
AT gonzalezantonio patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations
AT martinmariam patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations
AT jimenezalejandro patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations
AT cerropurificacion patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations
AT porterojulian patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations
AT barreramanuela patientswithhepatocellularcarcinomathatdieduringthefirstyearoflivertransplantationhavehighbloodsfaslconcentrations